Philadelphia-based AUM LifeTech develops RNA-targeting therapeutics through its proprietary AUM silence antisense oligonucleotide platform, which is designed to silence or regulate disease-linked RNA without an external delivery vehicle. Founded by biotechnology entrepreneur Veenu Aishwarya, the company is pursuing preclinical treatments for genetically defined diseases, including an anti-FOXP3 cancer-immunotherapy program developed with Children’s Hospital of Philadelphia. Its work also includes a Parkinson’s disease program conducted with the University of Pennsylvania.
GeneLancet BiosciencesEstablished in November 2019, Doylestown-based GeneLancet Biosciences develops in vivo gene and cell therapies built around its proprietary single-molecule guide RNA, or LgRNA. The company is advancing LgRNA-conjugate-guided STAR and DuoSTAR genome editors for precise treatments aimed at serious diseases including neurodegenerative disorders, cancer and chronic hepatitis B. Its platform emphasizes scalable, high-purity guide RNA and editing approaches designed to avoid double-strand DNA breaks and support repeat or multiplex treatment strategies.541714DOYLESTOWN, PA
Franklin BiolabsFranklin Biolabs is a Philadelphia life-sciences company whose team has helped shape genetic medicine for more than four decades, with expertise carried forward from the University of Pennsylvania’s Penn Vector Core. Today, it serves biotechnology, pharmaceutical, and academic researchers as a preclinical CRO, helping advance therapies from early research toward clinical development.325414PHILADELPHIA, PA
Generian PharmaceuticalsFormed by UPMC Enterprises, Generian Pharmaceuticals is a Boston- and Pittsburgh-based preclinical biotechnology company developing orally available small-molecule therapeutics for difficult-to-drug diseases often dominated by biologics. Its discovery platform screens proteins in their native cellular environment, then combines target-binding data with disease-relevant phenotypic testing to advance candidates that modulate protein activity, stability, or degradation. The company’s research includes proprietary programs and a collaboration with Astellas for novel targets.
LifePulse CorporationLifePulse Corporation develops and manufactures its US-engineered Intellipulse® platform to deliver therapeutics directly into cells, with a focus on targeted oncology in human and veterinary medicine. Founded by Gary Strange, the Tampa Bay company builds on more than three decades of research, $35 million in non-dilutive funding, and over 100 issued patents. Its animal-health division has treated hundreds of dogs, cats, and horses since 2022, while its human-health program is advancing toward pancreatic-tumor trials.NEW YORK, NY